User:Mr. Ibrahem/Sorafenib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Sorafenib
Clinical data
Trade namesNexavar, others
Other namesNexavar
Sorafenib tosylate
AHFS/Drugs.comMonograph
MedlinePlusa607051
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classProtein kinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability38–49%
Protein binding99.5%
MetabolismLiver oxidation and glucuronidation (CYP3A4 & UGT1A9-mediated)
Elimination half-life25–48 hours
ExcretionFaeces (77%) and urine (19%)
Identifiers
  • 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]
    phenoxy]-N-methyl-pyridine-2-carboxamide
Chemical and physical data
FormulaC21H16ClF3N4O3
Molar mass464.83 g·mol−1
3D model (JSmol)
  • CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
  • InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) checkY
  • Key:MLDQJTXFUGDVEO-UHFFFAOYSA-N checkY
  (verify)

Sorafenib, sold under the brand name Nexavar, is a medication used to treat renal cell carcinoma, hepatocellular carcinoma, and certain types of thyroid cancer.[2][1] It is taken by mouth.[1]

Common side effects include diarrhea, rash, hair loss, infection, rash, and tiredness.[1] Other side effects may include a heart attack, gastrointestinal perforation, liver problems, bleeding, and high blood pressure.[1] Use in pregnancy or breastfeeding may harm the baby.[4] It is a protein kinase inhibitor.[1]

Sorafenib was approved for medical use in the United States in 2005 and Europe in 2006.[2][1] In the United Kingdom 4 weeks of treatment costs the NHS about £3,600 as of 2021.[3] This amount in the United States costs about 20,200 USD.[5]

References[edit]

  1. ^ a b c d e f g h i "Nexavar". Archived from the original on 14 October 2021. Retrieved 14 October 2021.
  2. ^ a b c "SORAfenib Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 14 October 2021.
  3. ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1056. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  4. ^ "Sorafenib (Nexavar) Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 14 October 2021.
  5. ^ "Nexavar Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 14 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Sorafenib&oldid=1164798784"